Bristol Sprycel Clears FDA As First Second-Line Leukemia Agent
Executive Summary
Bristol-Myers Squibb will be required to submit follow-up data from ongoing clinical trials to convert the accelerated approval of Sprycel for chronic myeloid leukemia to full approval, FDA said after clearing dasatinib June 28
You may also be interested in...
Orencia Outperforming Rituxan In RA, Bristol Says; Branded DTC To Start Soon
Physicians more frequently prescribe Bristol-Myers Squibb's Orencia than Genentech/Biogen Idec's Rituxan for rheumatoid arthritis, Bristol Worldwide Pharmaceuticals President Lamberto Andreotti said
Orencia Outperforming Rituxan In RA, Bristol Says; Branded DTC To Start Soon
Physicians more frequently prescribe Bristol-Myers Squibb's Orencia than Genentech/Biogen Idec's Rituxan for rheumatoid arthritis, Bristol Worldwide Pharmaceuticals President Lamberto Andreotti said
Bristol Is Not For Sale, CEO Says; Plavix Woes Partly Offset By Other Products
Bristol-Myers Squibb Interim CEO Jim Cornelius is becoming more confident the company can operate as an independent entity going forward